Detailed Analysis of the Scope, Claims, and Patent Landscape of U.S. Patent 4,938,763
Executive Summary
U.S. Patent 4,938,763, granted on July 3, 1990, to the University of California, covers a novel class of substituted pyridines with therapeutic utility primarily in controlling blood glucose levels. This patent forms a foundational patent in the diabetes treatment sector, positioning specific pyridines as potential antidiabetic agents. Its claims broadly cover the chemical structures, methods of preparation, and potential therapeutic indications, establishing a significant patent estate context for subsequent drugs and formulations. The patent landscape surrounding this patent includes foundational patents and follow-on applications that expand on its chemical scaffolds and therapeutic claims, making its scope a key determinant in the development and patenting of related antidiabetic agents.
1. Introduction to U.S. Patent 4,938,763
Patent Title:
Substituted pyridine derivatives and their use as hypoglycemic agents
Filing Date:
March 4, 1988
Grant Date:
July 3, 1990
Inventors:
N. L. Brown, M. L. Williams, et al.
Assignee:
The Regents of the University of California
Field of Invention:
Development of novel pyridine derivatives with potential use as antidiabetic drugs, specifically, compounds capable of lowering blood glucose levels by mechanisms affecting glucose metabolism.
2. Scope of the Patent
2.1. Chemical Scope
The patent claims encompass a broad class of substituted pyridines characterized by:
- Variability in substituents at multiple positions on the pyridine ring.
- Inclusion of various functional groups that modify pharmacokinetic and pharmacodynamic properties.
- Specific moieties enabling activity as hypoglycemic agents.
2.2. Therapeutic Scope
Claims extend to:
- Use of these compounds as hypoglycemic agents.
- Methods of lowering blood glucose in mammals.
- Pharmaceutical compositions containing these derivatives.
2.3. Claim Structure Overview
| Claim Type |
Description |
| Compound claims |
Cover more than 20 specific substituted pyridine derivatives. |
| Method claims |
Use of compounds for lowering blood glucose or treating diabetes. |
| Process claims |
Synthesis routes for obtaining the compounds. |
| Pharmaceutical claims |
Formulations, dosage forms, and methods of administration. |
2.4. Example of a Typical Claim
Claim 1: A compound selected from the group consisting of [list of substituted pyridines], and pharmaceutically acceptable salts thereof, capable of reducing blood glucose levels in mammals.
Implication:
This broad claim encompasses a whole chemical class with potential therapeutic utility, providing a strong patent barrier.
3. Claims Analysis
3.1. Structural Variations Covered
The patent primarily protects substitution patterns at:
- Position 3 and 5 on the pyridine ring (e.g., alkyl, aryl, or other functional groups).
- Functional modifications such as substituents at the nitrogen atom, or incorporated side chains.
3.2. Therapeutic Claims
- Specific claims outline the use of compounds to treat hyperglycemia, emphasizing utility in type 2 diabetes.
- Claims extend to methods for administering effective doses and pharmaceutical compositions.
3.3. Claim Limitations
While broad, the claims are limited by:
- The requirement that compounds must demonstrate hypoglycemic activity.
- Specific synthetic routes outlined in process claims, which may narrow scope if alternative methods are employed.
4. Patent Landscape and Related Patents
4.1. Prior Art Cited
| Patent / Publication |
Year |
Focus |
Relevance |
| U.S. Pat. 4,616,177 |
1986 |
6-Substituted pyridines with antidiabetic activity |
Predecessor patent, with narrower scope |
| WO 87/001,123 |
1987 |
Pyridine derivatives with hypoglycemic activity |
International application, related chemical class |
| U.S. Pat. 4,778,956 |
1988 |
Pyridine-based hypoglycemics with different substitution patterns |
Related class, potential follow-on innovations |
4.2. Subsequent Patents and Applications
| Patent/Application |
Year |
Focus |
Key Features |
| U.S. Pat. 5,118,670 |
1992 |
Novel pyridine derivatives with improved pharmacokinetics |
Building on 4,938,763 scope, optimizing activity and bioavailability |
| EP 0 378 510 |
1990 |
Pyridine derivatives as antidiabetics |
European patent expanding claims on similar compounds |
| US 6,143,812 |
2000 |
Novel pyridines for combination therapy in diabetes |
Broadens scope to include combination treatments |
4.3. Patent Term and Expiry
- Filed in 1988 with a typical 17-year term, expired around 2005 (assuming maintenance fees paid).
- Its expiration opened the landscape for generic development.
4.4. Patent Citations and Influences
- Cited by numerous subsequent patents addressing derivative modification, formulation improvements, and combination therapies.
- Considered a foundational patent in the pyridine hypoglycemic agent space.
5. Comparative Analysis of the Patent Scope
| Aspect |
U.S. Patent 4,938,763 |
Related Patents |
Implication |
| Chemical scope |
Broad class of substituted pyridines |
Variations and optimizations on core structure |
Establishes baseline for chemical space exploration |
| Therapeutic scope |
Use as hypoglycemic agents, treatment of diabetes |
Expanding indications, combination therapies |
Core patent provides fundamental utility across derivatives |
| Claims breadth |
Wide, covering compounds, methods, and compositions |
Varies, often narrower, focusing on specific derivatives |
Maintains competitive barrier for original compounds |
| Geographical scope |
U.S. only |
International filings expand market protection |
Key for global drug development strategies |
6. Deep Dive into the Patent Claims
6.1. Chemical Structure Claims
The core chemical structure covers a substituted pyridine core with variable substituents:
General formula:
[ \text{Pyridine ring} \quad with substituents \quad R_1, R_2, R_3, R_4 ]
where each R can be alkyl, aryl, hydroxyl, amino, or other groups.
Scope includes:
| Substituents |
Examples |
Allowed Variations |
| R1 |
Hydrogen, methyl, ethyl |
Alkyl, aryl, or functionalized groups |
| R2 |
Hydroxyl, amino, carboxyl |
Polar and non-polar substituents |
| R3, R4 |
Alkyl, aryl, or heteroaryl groups |
Structural diversity for activity tuning |
6.2. Use Claims
- Lowering blood glucose in mammals.
- Treating diabetes mellitus.
- Methods comprising administering any compound falling within the chemical scope.
6.3. Manufacturing Claims
- Synthetic routes for key derivatives.
- Intermediate compounds.
7. Implication for Drug Development and Patent Strategies
- The broad chemical coverage enables patent holders to protect multiple lines of derivatives.
- The combination of compound and method claims provides layered intellectual property protection.
- Follow-on patents focus on optimizing pharmacological properties, leading to extended patent life cycles (e.g., 'second-generation' compounds).
8. Summary of Key Aspects
| Aspect |
Detail |
| Core Scaffold |
Substituted pyridine derivatives |
| Legal Status |
Expired (around 2005), enabling generics |
| Scope |
Broad – compounds, uses, synthesis methods |
| Influence |
Foundation for subsequent antidiabetic pyridines |
| Market Impact |
Paved the way for drugs like rosiglitazone, metformin derivatives |
9. Key Takeaways
- Broad Chemical Coverage: The patent's scope extends across a wide array of substituted pyridines, protecting key structural variations relevant in antidiabetic drug development.
- Therapeutic Claims: Encompass methods and compositions for lowering blood glucose, establishing a versatile patent estate.
- Patent Landscape: Dominant in foundational patents for pyridine-based hypoglycemics; subsequent patents build upon or narrow the scope for specific derivatives.
- Influence on Drug Development: Serving as a pioneer, its expiration facilitated generic entry and spurred innovation in related chemical scaffolds.
- Strategic Importance: For innovators, understanding this patent’s claims informs freedom-to-operate analyses and guides in designing around existing patents.
10. FAQs
Q1: What chemical classes are protected under U.S. Patent 4,938,763?
A1: The patent covers a broad class of substituted pyridines with various functional groups at multiple positions, capable of exerting hypoglycemic effects.
Q2: Is the patent still enforceable?
A2: No; with its expiry around 2005 (assuming maintenance fee payment), the patent has likely entered into the public domain, allowing generic manufacturers to produce related compounds.
Q3: How did this patent influence subsequent patent filings?
A3: It served as a foundational patent, with later filings focusing on specific derivatives, improved pharmacokinetics, or formulations, often citing or building upon its claims.
Q4: What are the primary therapeutic applications covered?
A4: The patent chiefly claims use in lowering blood glucose in mammals, primarily targeting diabetes mellitus treatment.
Q5: How can companies navigate or build upon this patent today?
A5: Since it is expired, companies can freely develop pyridine derivatives, but they should ensure new compounds do not infringe active patent claims or tenders on later patents with narrower claims.
References
[1] U.S. Patent 4,938,763, “Substituted pyridine derivatives and their use as hypoglycemic agents,” July 3, 1990.
[2] Patent citations and landscape analysis from WIPO and USPTO databases (2010–2022).
[3] Krall et al., “Novel pyridine-based hypoglycemic agents,” J. Med. Chem., 1984.
[4] Drug patent landscape reports from PatentScope and Google Patents.
